Eva Fortea Analyst PerformanceVice President - Biotechnology at Wells Fargo & CompanyEva Fortea is a stock analyst at Wells Fargo & Company focused in the medical sector, covering 13 publicly traded companies. Over the past year, Eva Fortea has issued 26 stock ratings, including buy, hold, and sell recommendations. While full access to Eva Fortea's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Eva Fortea's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings26 Last 0 YearsBuy Recommendations53.85% 14 Buy RatingsCompanies Covered13 Unique Companies Ratings Distribution26RatingsDistribution of strong buy, buy, hold, and sell ratings by Eva Fortea.RatingPercentageCount Strong Buy0.0%0 ratings Buy53.8%14 ratings Hold42.3%11 ratings Sell3.8%1 ratingsOut of 26 total stock ratings issued by Eva Fortea at Wells Fargo & Company, the majority (53.8%) have been Buy recommendations, followed by 42.3% Hold and 3.8% Sell.Best & Worst CallsThis analyst does not have any ratings with enough history to determine best and worst calls.Exchange CoverageExchangePercentageCountNASDAQ92.3% of companies on NASDAQ12 companiesNYSE7.7% of companies on NYSE1 companyEva Fortea, an analyst at Wells Fargo & Company, currently covers 13 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical12 companies92.3%Manufacturing1 company7.7%Eva Fortea of Wells Fargo & Company specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE10 companies76.9%MED - DRUGS2 companies15.4%PHARMACEUTICAL PREPARATIONS1 company7.7% Eva Fortea's Ratings History at Wells Fargo & Company Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsKNSAKiniksa Pharmaceuticals International4/29/2026Boost Price Target$53.89$57.00Overweight$0.0000.00% ROIRLAYRelay Therapeutics4/28/2026Boost Price Target$14.95$21.00Overweight$0.0000.00% ROIIDYAIDEAYA Biosciences4/14/2026Boost Price Target$31.45$48.00Overweight$0.0000.00% ROIBCAXBicara Therapeutics3/31/2026Boost Price Target$19.52$16.00Equal Weight$0.0000.00% ROISTROSutro Biopharma3/24/2026Upgrade$21.33$27.00Overweight$0.0000.00% ROIRLAYRelay Therapeutics3/17/2026Boost Price Target$10.13$17.00Overweight$0.0000.00% ROIGMABGenmab A/S3/2/2026Initiated Coverage$29.44$40.00Overweight$0.0000.00% ROIRLAYRelay Therapeutics2/27/2026Boost Price Target$10.59$15.00Overweight$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International2/25/2026Boost Price Target$41.86$53.00Overweight$0.0000.00% ROIRCUSArcus Biosciences2/12/2026Set Price Target$21.37$23.00Equal Weight$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. RCUSArcus Biosciences2/12/2026Downgrade$19.88$23.00Equal Weight$0.0000.00% ROIEXELExelixis2/11/2026Boost Price Target$42.17$35.00Equal Weight$0.0000.00% ROIRLAYRelay Therapeutics12/12/2025Upgrade$7.79$13.00Overweight$0.0000.00% ROIZYMEZymeworks12/12/2025Upgrade$24.94$33.00Overweight$0.0000.00% ROIZYMEZymeworks11/19/2025Boost Price Target$22.99$25.00Cautious$0.0000.00% ROIBCAXBicara Therapeutics11/11/2025Boost Price Target$13.84$11.00Equal Weight$0.0000.00% ROIZYMEZymeworks11/7/2025Boost Price Target$16.80$17.00Equal Weight$0.0000.00% ROIRLAYRelay Therapeutics11/7/2025Boost Price Target$6.19$6.00Equal Weight$0.0000.00% ROIIMCRImmunocore10/31/2025Initiated Coverage$32.38$60.00Overweight$0.0000.00% ROIZYMEZymeworks10/24/2025Initiated Coverage$17.41$15.00Equal Weight$0.0000.00% ROIRCUSArcus Biosciences10/20/2025Boost Price Target$16.74$29.00Overweight$0.0000.00% ROIMRUSMerus9/29/2025Reiterated Rating$94.15$97.00Equal Weight$0.0000.00% ROIMRUSMerus9/29/2025Downgrade$93.67$97.00Equal Weight$0.0000.00% ROIITOSiTeos Therapeutics8/7/2025Lower Price Target$10.13$11.00Equal Weight$0.0000.00% ROIXNCRXencor8/7/2025Lower Price Target$7.19$27.00Overweight$0.0000.00% ROIRCUSArcus Biosciences8/7/2025Lower Price Target$9.35$25.00Overweight$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTruist FinancialTD CowenPiper SandlerRaymond James FinancialStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
